Need help finding what you are looking for?
Contact Us
PUBLISHER: IMARC | PRODUCT CODE: 1379173
PUBLISHER: IMARC | PRODUCT CODE: 1379173
Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
PUBLISHED:
PAGES: 148 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Abstract
The global hematologic malignancies market size reached US$ 55.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 93.2 Billion by 2028, exhibiting a growth rate (CAGR) of 9.1% during 2022-2028.
Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.
Hematologic Malignancies Market Trends:
The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapy and end user.
Breakup by Type:
Leukemia
Lymphoma
Multiple Myeloma
Others
Breakup by Therapy:
Chemotherapy
Radiotherapy
Immunotherapy
Stem Cell Transplantation
Others
Breakup by End User:
Hospitals
Diagnostics Centers
Research Centers
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.
Key Questions Answered in This Report:
- How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global hematologic malignancies market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the therapy?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global hematologic malignancies market and who are the key players?
- What is the degree of competition in the industry?
Product Code: SR112023A4133
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Hematologic Malignancies Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Leukemia
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Lymphoma
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Multiple Myeloma
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Therapy
- 7.1 Chemotherapy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Radiotherapy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Immunotherapy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Stem Cell Transplantation
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Diagnostics Centers
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Research Centers
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 AstraZeneca plc
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 Bristol-Myers Squibb Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Eli Lilly and Company
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 F. Hoffmann-La Roche Ltd
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.6 GlaxoSmithKline plc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Johnson & Johnson
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Merck & Co. Inc
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Novartis AG
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Pfizer Inc.
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
- 14.3.10.4 SWOT Analysis
- 14.3.11 Sanofi S.A.
- 14.3.11.1 Company Overview
- 14.3.11.2 Product Portfolio
- 14.3.11.3 Financials
- 14.3.11.4 SWOT Analysis
- 14.3.12 Takeda Pharmaceutical Company Limited
- 14.3.12.1 Company Overview
- 14.3.12.2 Product Portfolio
- 14.3.12.3 Financials
- 14.3.12.4 SWOT Analysis
- 14.3.1 AbbVie Inc.
Product Code: SR112023A4133
List of Figures
- Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
- Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2017-2022
- Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2023-2028
- Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2022
- Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2022
- Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2022
- Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2022
- Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
- Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
- Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2022
- Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
- Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
- Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
- Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2022 and 2028
- Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2023-2028
- Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
- Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2023-2028
- Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2023-2028
- Table 6: Global: Hematologic Malignancies Market: Competitive Structure
- Table 7: Global: Hematologic Malignancies Market: Key Players
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.